Related references
Note: Only part of the references are listed.Intraocular pressure-lowering effects of ripasudil, a rho-kinase inhibitor, and selective laser trabeculoplasty as adjuvant therapy in patients with uncontrolled glaucoma
Koichi Ono et al.
INTERNATIONAL OPHTHALMOLOGY (2021)
Glaucoma in Adults-Screening, Diagnosis, and Management A Review
Joshua D. Stein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles
Takayuki Kamiya et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2021)
Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Nada M. El Hoffy et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E2 receptor EP2 subtype
Changxiu Qu et al.
SCIENCE ADVANCES (2021)
Tackling retinal ganglion cell apoptosis in glaucoma: role of adenosine receptors
Puneet Agarwal et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study
Shunsuke Nakakura et al.
BMJ OPEN (2021)
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Nikki A. Mehran et al.
EYE (2020)
Transduction optimization of AAV vectors for human gene therapy of glaucoma and their reversed cell entry characteristics
Laura Rodriguez-Estevez et al.
GENE THERAPY (2020)
Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor
Riyo Matsumura et al.
INTERNATIONAL OPHTHALMOLOGY (2020)
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and-2
Sanjay Asrani et al.
ADVANCES IN THERAPY (2020)
New techniques and strategies in drug discovery
Jintong Du et al.
CHINESE CHEMICAL LETTERS (2020)
Neuroprotection: A versatile approach to combat glaucoma
Santoshi Naik et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study
Makoto Aihara et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2020)
Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study
Akiko Futakuchi et al.
SCIENTIFIC REPORTS (2020)
AR12286 Alleviates TGF-beta-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery
Wen-Sheng Cheng et al.
MOLECULES (2020)
An update on ripasudil for the treatment of glaucoma and ocular hypertension
V Testa et al.
DRUGS OF TODAY (2020)
Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection
Sentaro Kusuhara et al.
CLINICAL OPHTHALMOLOGY (2020)
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Makoto Aihara et al.
JOURNAL OF GLAUCOMA (2019)
Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure
Susan S. Lee et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2019)
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial
Sanjay Asrani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Development of a Novel Intraocular-Pressure-Lowering Therapy Targeting ATX
Norimichi Nagano et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2019)
Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Claudiu T. Supuran et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Makoto Aihara et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2019)
Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
Hidenobu Tanihara et al.
ADVANCES IN THERAPY (2019)
Effects of ripasudil, a rho kinase inhibitor, on blood flow in the optic nerve head of normal rats
Yasushi Wada et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
Global Blindness: The Progress We Are Making and Still Need to Make
Hugh R. Taylor
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2019)
Effect of ripasudil on diabetic macular edema
Yoshiro Minami et al.
SCIENTIFIC REPORTS (2019)
Netarsudil Ophthalmic Solution 0.02%: First Global Approval
Sheridan M. Hoy
DRUGS (2018)
Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Sheridan M. Hoy
DRUGS (2018)
Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Ryo Iwamura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
Megan E. Cavet et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2018)
Targets of Neuroprotection in Glaucoma
Shaoqing He et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2018)
Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Cheng-Wen Lin et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2018)
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Angelo P. Tanna et al.
OPHTHALMOLOGY (2018)
Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma
Artemis Matsou et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Eydie Miller Ellis et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension
Paul L. Kaufman
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma
Toshihiro Inoue et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study
Michael S. Berlin et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Richard A. Lewis et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase
Tomoyuki Isobe et al.
XENOBIOTICA (2016)
Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Kazuhide Kawase et al.
ADVANCES IN THERAPY (2016)
Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Jill M. Sturdivant et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Synthesis and pharmacological properties of naturally occurring prenylated and pyranochalcones as potent anti-inflammatory agents
Kongara Damodar et al.
CHINESE CHEMICAL LETTERS (2016)
Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Alon Harris et al.
JOURNAL OF GLAUCOMA (2016)
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
Jonathan S. Myers et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2016)
Improved thromboresistance and analytical performance of intravascular amperometric glucose sensors using optimized nitric oxide release coatings
Alexander K. Wolf et al.
CHINESE CHEMICAL LETTERS (2015)
Double-masked, Randomized, Dose-Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure
Jason Bacharach et al.
OPHTHALMOLOGY (2015)
A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Fumitaka Suto et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2015)
IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys
Shinsaku Yamane et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2015)
Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension
Liang Lin et al.
ANNALS OF PHARMACOTHERAPY (2014)
Prostanoid Receptor EP2 as a Therapeutic Target
Thota Ganesh
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways
Nelson S. Winkler et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2014)
Nitric Oxide (NO): An Emerging Target for the Treatment of Glaucoma
Megan E. Cavet et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
The Novel Rho Kinase (ROCK) Inhibitor K-115: A New Candidate Drug for Neuroprotective Treatment in Glaucoma
Kotaro Yamamoto et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Adenosine, adenosine receptors and glaucoma: An updated overview
Yisheng Zhong et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors
Sandro Boland et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
SmI2-Mediated Intermolecular Coupling of γ-Lactam N-α-Radicals with Activated Alkenes: Asymmetric Synthesis of 11-Hydroxylated Analogues of the Lead Compounds CP-734432 and PF-04475270
Kong-Zhen Hu et al.
JOURNAL OF ORGANIC CHEMISTRY (2013)
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Kang Zhang et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
A Practical Synthesis of (S)-tert-Butyl 3-Methyl-1,4-diazepane-1-carboxylate, the Key Intermediate of Rho-Kinase Inhibitor K-115
Noriaki Gomi et al.
SYNTHESIS-STUTTGART (2012)
Ocular Drug Delivery for Glaucoma Management
Nathan Gooch et al.
Pharmaceutics (2012)
A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension
Ronald A. Schachar et al.
CURRENT EYE RESEARCH (2011)
Update on the role of alpha-agonists in glaucoma management
Stella Arthur et al.
EXPERIMENTAL EYE RESEARCH (2011)
Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2α agonist, in preclinical models
Achim H. P. Krauss et al.
EXPERIMENTAL EYE RESEARCH (2011)
A PRACTICAL SYNTHESIS OF NOVEL RHO-KINASE INHIBITOR, (S)-4-FLUORO-5-(2-METHYL-1,4-DIAZEPAN-1-YLSULFONYL)- ISOQUINOLINE
Noriaki Gomi et al.
HETEROCYCLES (2011)
Structural basis of substrate discrimination and integrin binding by autotaxin
Jens Hausmann et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Crystal structure of autotaxin and insight into GPCR activation by lipid mediators
Hiroshi Nishimasu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
The Role of the Prostaglandin EP4 Receptor in the Regulation of Human Outflow Facility
Lindsay H. Millard et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Diurnal Variation of Visual Function and the Signs and Symptoms of Dry Eye
Pamela M. Walker et al.
CORNEA (2010)
A Novel Nitric Oxide Releasing Prostaglandin Analog, NCX 125, Reduces Intraocular Pressure in Rabbit, Dog, and Primate Models of Glaucoma
Valentina Borghi et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
Dry eye in 2008
Mark B. Abelson et al.
CURRENT OPINION IN OPHTHALMOLOGY (2009)
Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models
Ganesh Prasanna et al.
EXPERIMENTAL EYE RESEARCH (2009)
Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics
Ciro Costagliola et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides
Ciro Costagliola et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Pharmacokinetic-Pharmacodynamic and Response Sensitization Modeling of the Intraocular Pressure-Lowering Effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270)
Kenneth T. Luu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork
Min Zhang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2008)
Aqueous humor outflow: What do we know? Where will it lead us?
Michael P. Fautsch et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey
Siv F. E. Nilsson et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats
S Mita et al.
JOURNAL OF HYPERTENSION (2005)
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia
L McCullough et al.
JOURNAL OF NEUROSCIENCE (2004)
Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma
F Galassi et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2004)
Isoprostane 8-epi-prostaglandin F2 alpha decreases lymph capillary pressure in patients with primary lymphedema
BR Amann-Vesti et al.
JOURNAL OF VASCULAR RESEARCH (2003)
A1-, A2A- and A3-subtype adenosine receptors modulate intraocular pressure in the mouse
MY Avila et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Share Paper
